SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

TD1092

Cat. No.: HY-151966

Molecular Formula: $C_{55}H_{70}N_8O_9$

Molecular Weight: 987.19

Target: IAP; PROTACs; Caspase

Pathway: Apoptosis; PROTAC

Storage: 4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (101.30 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Mass / Solvent / Concentration	1 mg	5 mg	10 mg
1 mM	1.0130 mL	5.0649 mL	10.1298 mL
5 mM	0.2026 mL	1.0130 mL	2.0260 mL
10 mM	0.1013 mL	0.5065 mL	1.0130 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

TD1092 is a pan-IAP degrader, degrades cIAP1, cIAP2, and XIAP. TD1092 activates Caspase 3/7, and promotes cancer cells apoptosis via IAP degradation. TD1092 inhibits TNFα mediated NF-κB pathway and reduces the phosphorylation of IKK, IkB α, p65, and p38. TD1092 can act as PROTAC, and is used for cancer research[1].

IC_{50} & Target

cIAP1	cIAP2	XIAP	Caspase 3
Caspase-7			

In Vitro

TD1092 (0.1 μM-10 μM; 0.5-6 h) potently degrades cIAP1, cIAP2, and XIAP in a dose- and time-dependent manner[1].
TD1092 (0.01, 0.1 and 1 μM; 18 h) activates caspase 3/7 in MCF-7 cells[1].
TD1092 (1 μM; 48 h and 72 h) promotes cancer cell death[1].
TD1092 (0.1 μM; 24 h) inhibits TNFα-induced migration and invasion against triple-negative breast cancer cells[1].
TD1092 (1 μM; 6 h) inhibits TNFα-induced NF-κB signaling pathway and epithelial-mesenchymal transition (EMT) via IAP degradation[1].
TD1092 (1 μM; 72 h) inhibits MCF-7 cells growth with an IG_{50} value of 0.395 μM[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	MCF-7 cells
Concentration:	(1) 0, 0.1, 1, 10 μM or 0.1 μM (2) 0.1 μM, with or without 100 ng/mL TNFα
Incubation Time:	18 hours or 0.5, 1, 2, 4, 6 hours for (1) and 4 hours for (2)
Result:	Dose- and time-dependently decreases the protein level of cIAP1, cIAP2, and XIAP. Inhibited the phosphorylation of IKK, IkBα, p65, and p38 mediated by TNFα. Counterbalanced the effect of TNFα on the levels of E-cadherin (CDH1; an epithelial marker) and vimentin (VIM; a mesenchymal marker).

Cell Migration Assay [1]

Cell Line:	MDA-MB-231 and MDA-MB-157 cells
Concentration:	0.1 μM; with or without 100 ng/mL TNFα
Incubation Time:	24 hours
Result:	Inhibited TNFα-induced (100 ng/mL) migration and invasion against two triple-negative breast cancer (TNBC; MDA-MB-231 and MDA-MB-157) cell lines.

REFERENCES

[1]. Park S, et al. Discovery of pan-IAP degraders via a CRBN recruiting mechanism. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114910.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA